Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Trial ID or NCT#

NCT00790335

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic syndrome(PTS)in patients with symptomatic proximal deep vein thrombosis(DVT)as compared with optimal standard DVT therapy alone.

Official Title

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis--The ATTRACT Trial

Eligibility Criteria

Ages Eligible for Study: 16 Years to 75 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Symptomatic proximal DVT involving the iliac, common femoral, and/or femoral vein.
Exclusion Criteria:
  1. - Age less than 16 years or greater than 75 years. - Symptom duration > 14 days for the DVT episode in the index leg (i.e., non-acute DVT). - In the index leg: established PTS, or previous symptomatic DVT within the last 2 years. - In the contralateral (non-index) leg: symptomatic acute DVT a) involving the iliac and/or common femoral vein; or b) for which thrombolysis is planned as part of the initial therapy. - Limb-threatening circulatory compromise. - Pulmonary embolism with hemodynamic compromise (i.e., hypotension). - Inability to tolerate PCDT procedure due to severe dyspnea or acute systemic illness. - Allergy, hypersensitivity, or thrombocytopenia from heparin, rt-PA, or iodinated contrast, except for mild-moderate contrast allergies for which steroid pre-medication can be used. - Hemoglobin < 9.0 mg/dl, INR > 1.6 before warfarin was started, or platelets < 100,000/ml. - Moderate renal impairment in diabetic patients (estimated glomerular filtration rate [GFR] < 60 ml/min) or severe renal impairment in non-diabetic patients (estimated GFR < 30 ml/min). - Active bleeding, recent (< 3 mo) GI bleeding, severe liver dysfunction, bleeding diathesis. - Recent (< 3 mo) internal eye surgery or hemorrhagic retinopathy; recent (< 10 days) major surgery, cataract surgery, trauma, cardiopulmonary resuscitation, obstetrical delivery, or other invasive procedure. - History of stroke or intracranial/intraspinal bleed, tumor, vascular malformation, aneurysm. - Active cancer (metastatic, progressive, or treated within the last 6 months). Exception: patients with non-melanoma primary skin cancers are eligible to participate in the study. - Severe hypertension on repeated readings (systolic > 180 mmHg or diastolic > 105 mmHg). - Pregnant (positive pregnancy test, women of childbearing potential must be tested). - Recently (< 1 mo) had thrombolysis or is participating in another investigational drug study. - Use of a thienopyridine antiplatelet drug (except clopidogrel) in the last 5 days. - Life expectancy < 2 years or chronic non-ambulatory status. - Inability to provide informed consent or to comply with study assessments (e.g. due to cognitive impairment or geographic distance).

Investigator(s)

Gloria Hwang, MD
Gloria Hwang, MD
Interventional radiologist
Clinical Professor, Radiology
David Hovsepian, MD
David Hovsepian, MD
Interventional radiologist, Radiologist
Clinical Professor, Radiology
Caroline Berube
Caroline Berube
Hematologist
Clinical Associate Professor, Medicine - Hematology
John D. Louie, MD
John D. Louie, MD
Interventional radiologist
Clinical Associate Professor, Radiology
Donald Schreiber
Donald Schreiber
Emergency medicine doctor
Associate Professor of Emergency Medicine at the Stanford University Medical Center, Emeritus
Daniel Sze, MD, PhD
Daniel Sze, MD, PhD
Interventional radiologist
Professor of Radiology (Interventional Radiology)
Nishita Kothary, MD
Nishita Kothary, MD
Interventional radiologist
Professor of Radiology (Interventional Radiology)

Contact us to find out if this trial is right for you.

CONTACT

Kamil Unver
(650) 725-9810